Skip to main content

BRAF V600 Mutation clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

    open to eligible people ages 18 years and up

    This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally advanced or metastatic solid tumors who have no effective standard treatment options available, as monotherapy in patients with documented BRAF V600 mutation, or in combination with cobimetinib (Cotellic®) in adult patients who have documented BRAF mutation and progressive disease or intolerance to at least one prior line of systemic therapy.

    San Francisco, California and other locations

Our lead scientists for BRAF V600 Mutation research studies include .

Last updated: